Lonza Licenses Blood-Brain Barrier Delivery Technology to China Medical System
Key Points
- Lonza granted China Medical System exclusive global rights to its NeuroPortal TfR1 technology for up to two neurodegenerative disease products, the platform's first license since Lonza acquired it.
- NeuroPortal uses transferrin receptor 1 binding variants to carry biologic drugs across the blood-brain barrier, and preclinical studies outperformed a leading industry benchmark in IgG fusion proteins and GlycoConnect formats.
- Lonza will receive an upfront payment plus development and commercial milestone payments and royalties; financial terms were not disclosed, and Lonza can still license the technology for other targets.
Lonza has entered into a global exclusive licensing agreement with China Medical System Holdings Limited (CMS) covering its NeuroPortal™ transferrin receptor 1 (TfR1) technology, which is designed to improve the delivery of biologic drugs across the blood-brain barrier (BBB). Under the agreement, CMS will have exclusive development and commercial rights to use the technology in up to two products targeting neurodegenerative diseases. The deal represents the first license Lonza has granted since acquiring the TfR1 platform. The company will retain the ability to license the technology for other therapeutic targets and programs. Hong Kong-headquartered CMS develops and commercializes specialty medicines, with a focus that includes treatments for central nervous system (CNS) disorders.
The blood-brain barrier presents a longstanding obstacle in CNS drug development because it restricts the movement of many therapeutic molecules from the bloodstream into the brain. Lonza’s NeuroPortal™ TfR1 platform is intended to address this limitation through a range of binding variants with different receptor affinities. This allows developers to assess how receptor binding influences transport across the BBB and subsequent drug exposure in the brain.
According to Lonza, preclinical studies demonstrated that the platform outperformed a leading industry benchmark when incorporated into both immunoglobulin G (IgG) fusion proteins and molecules combined with the company’s GlycoConnect® technology. The latter platform supports site-specific antibody-drug conjugation.
The combination of NeuroPortal™ TfR1 with Lonza’s capabilities in protein expression, bioconjugation and molecular developability is intended to give drug developers additional options for designing and evaluating brain-targeted biologics. The technology supports both genetic fusion and bioconjugation approaches, allowing delivery strategies to be adapted to individual therapeutic candidates.
Financial terms were not disclosed. Lonza will receive an upfront payment, along with development and commercial milestone payments and royalties on net sales of products developed under the agreement.
“Delivering therapeutic molecules that can cross the blood-brain barrier remains a critical challenge in the development of treatments for neurodegenerative diseases,” says Peter Droc, Head of Licensing at Lonza. He noted that the platform gives developers the flexibility to evaluate different delivery approaches based on the characteristics of their therapeutic molecules.
The agreement represents an initial commercial application of the newly acquired technology, while leaving opportunities for additional partnerships across other disease areas. Lonza plans to present detailed findings from its NeuroPortal™ TfR1 platform at the 18th annual Protein & Antibody Engineering Summit (PEGS).
Find out more at www.lonza.com.
Total Page Views: 9

















